

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/568,098
				Filing Date	6/20/2006
				First Named Inventor	Steffen Goletz
				Art Unit	1636
				Examiner Name	Daniel M. Sullivan
Sheet	1	of	2	Attorney Docket Number	08358.0008-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁵
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁴
		AGRAWAL, et al., "Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2", <i>Natl. Med.</i> , 4(1):43-9 (1998)	
		DALL'OLIO, et al., "Expression of beta-galactoside alpha 2,6-sialyltransferase does not alter the susceptibility of human colon cancer cells to NK-mediated cell lysis." <i>Glycobiology</i> , 7:507-513 (1997)	
		GOLETZ, et al., "Antigen: the 'hidden' tumour antigen." <i>Adv. Exp. Med. Biol.</i> , 535:147-62 (2003)	
		NATALI, et al., "Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells." <i>Cancer Res</i> 1983; 43:660-666	
		PAHLSSON, et al., "Biochemical characterization of the O-glycans on recombinant glycoporphin as expressed in Chinese hamster ovary cells." <i>Glycoconj. J.</i> , 11:43-50 (1994)	
		PETERS, et al., "Preparation of immuno-therapeutic autologous tumour cell vaccines from solid tumours." <i>Cancer Res.</i> , 39:1353-1360 (1979)	
		SPRINGER, et al., "Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy." <i>J. Mol. Med.</i> , 75:594-602 (1997)	
		VAN RINSUM, et al., "Specific inhibition of human natural killer cell-mediated cytotoxicity by sialic acid and sialo-oligosaccharides." <i>Int. J. Cancer</i> , 38:915-922 (1986)	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/568,098
Filing Date	6/20/2006
First Named Inventor	Steffen Goletz
Art Unit	1636
Examiner Name	Daniel M. Sullivan
Attorney Docket Number	08358.0008-00000

Sheet 2 of 2

NONPATENT LITERATURE DOCUMENTS

	VOSHOL, et al., "Cell surface glycoconjugates as possible target structures for human natural killer cells: evidence against the involvement of glycolipids and N-linked carbohydrate chains." <i>Glycobiology</i> , 3:69-76 (1993)	
	WANG, et al., "Second-generation adenovirus vectors." <i>Nat. Med.</i> , 2:714-716 (1996)	
	WERKMEISTER, et al., "Modulation of K562 cells with sodium butyrate. Association of impaired NK susceptibility with sialic acid and analysis of other parameters." <i>Int. J. Cancer</i> , 32:71-78 (1983)	
	YU, et al., "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells." <i>Proc. Natl. Acad. Sci.</i> , 99:6047-6052 (1999)	
	ZHANG, et al., "A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells." <i>Cellular Immunology</i> , 176:156-165 (1997)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.